Clinical trials: Immune System Disease
B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of pevonedistat when given together with ibrutinib in participants with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or has stopped responding…
- Conditions
- B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT03479268
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Asthma
Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects
The primary objective of this study is to evaluate the dose response, efficacy, and safety of 4 different doses of salmeterol Spiromax (6.25, 12.5, 25, and 50 mcg) each combined with a fixed dose of fluticasone propionate (100…
- Trial name
- NCT01772368
- Testing
- Fp MDPI, FS MDPI, Advair Diskus
- Where
- 10 sites in United States
- Volunteers
- 72 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Thyroid Eye Disease
A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease
This trial will evaluate the effects of Lu AG22515 in adult men and women with moderate-to-severe thyroid eye disease (TED). TED is an autoimmune condition closely related to Graves' Disease.
- Trial name
- NCT06557850
- Testing
- Lu AG22515
- Where
- 6 sites in Bosnia and Herzegovina, Bulgaria and 1 more
- Volunteers
- 20 people
- Sponsor
- H. Lundbeck A/S
HIV Infections, Syphilis
Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC)
This study proposes to investigate the performance of existing and new technologies for HIV diagnosis, one of the key strategies for Ending the HIV Epidemic in the U.S.
- Trial name
- EHPOC (NCT04793750)
- Testing
- Cepheid GeneXpert HIV-1 Qual POC HIV VL test, DPP HIV-Syphilis test system, OraQuick
- Where
- 3 sites in United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Autoimmune Lymphoproliferative Syndrome, Lymphoma
Fluorodeoxyglucose Imaging Studies to Detect Lymphoma
Background: Autoimmune lymphoproliferative syndrome (ALPS) is a genetic disorder of the lymph system. People with ALPS often have swollen lymph nodes, especially in the neck and armpit.
- Trial name
- NCT01672918
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Allergic Rhinitis, Seasonal Allergic Rhinitis
Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis
The ragweed Ambrosia artemisiifolia is spreading in northern Europe due to climate change. The pollen are considered highly allergenic and might trigger allergy symptoms at much lower concentrations than e.g.
- Conditions
- Allergic Rhinitis, Seasonal Allergic Rhinitis, Ragweed Allergy, Birch Pollen Allergy
- Trial name
- UBAMBI (NCT05346718)
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Fraunhofer-Institute of Toxicology and Experimental Medicine
Type 1 Diabetes
Efficacy of Coordinated Insulin Boluses in Type 1 Diabetic Patients
A recent study suggests that, in Type 1 Diabetes (T1D) patients treated by insulin pumps, a better coordination of meal boluses and post prandial basal rate could reduce the importance of postprandial hyperglycaemias without…
- Trial name
- COBOL (NCT02229097)
- Testing
- Normal bolus, Coordinated bolus
- Where
- 3 sites in France
- Volunteers
- 17 people
- Sponsor
- University Hospital, Toulouse
Lymphoma
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find cancer cells and carry cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00770224
- Testing
- rituximab, tositumomab, cyclophosphamide
- Where
- 114 sites in United States
- Volunteers
- 87 people
- Sponsor
- SWOG Cancer Research Network
Mantle Cell Lymphoma, Lymphoma
Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma
The goal of this clinical research study is to learn if positron emission tomography (PET)/computed tomography (CT) scanning can be used to detect mantle cell lymphoma in the colon.
- Trial name
- NCT00541424
- Testing
- PET/CT Scanning
- Sponsor
- M.D. Anderson Cancer Center
HIV Infections
Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)
Didanosine is an effective anti-HIV drug, but it can cause stomach upset. This study tests a new form of didanosine, ddI EC, a coated pill that passes through the stomach more easily and hopefully will prevent stomach upset.
- Trial name
- NCT00002224
- Testing
- Nelfinavir mesylate, Stavudine, Didanosine
- Where
- 24 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
IgA Nephropathy (IgAN)
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN
- Trial name
- NCT07390123
- Testing
- HSK39297
- Where
- 9 sites in China
- Volunteers
- 370 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Brain and Nervous System, Eye and Orbit
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
The primary objective of Stage 1 is to evaluate the safety of nivolumab consolidation after completion of HD-MTX containing induction chemotherapy in older subjects with PCNSL in terms of a tolerated dose (based on dose-limiting…
- Trial name
- NCT04022980
- Testing
- Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences
Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase
Haploid Allogeneic Transplant Using the CliniMACS System
To assess the proportion of patients with donor neutrophil engraftment within 30 days of allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after transplantation.
- Conditions
- Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase, Myelodysplastic Syndrome (MDS) - High and Intermediate Risk, Non-Hodgkin's Lymphoma (NHL)
- Trial name
- NCT00185679
- Testing
- CliniMACS System
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ginna Laport
Asthma, Adherence, Medication
Evaluating Efficacy of Smart Device in Assisting With Inhaler Technique and Adherence
Asthma affects over 10 million children in the U.S., and poses a significant health and cost burden. Metered dose inhaler (MDI) is the most common method of treatment.
- Conditions
- Asthma, Adherence, Medication, Childhood Asthma
- Trial name
- MOMMIASTHMA1 (NCT04250779)
- Testing
- CapMedic smart inhaler device, Video-based guidance
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Landon Pediatric Foundation
Multiple Sclerosis
Virtual Reality and Robot Assisted Gait Training in Patients With Multiple Sclerosis
Multiple Sclerosis (MS), the most common non-traumatic cause of neurologic disability in young adults, affects mobility and ambulation in the majority of patients.
- Trial name
- GE-O-VR (NCT02896179)
- Testing
- Robot-assisted gait training group+VR, GEO
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Universita di Verona
Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
The purpose of this study is to determine the maximum tolerated dose (MTD), safety and toxicity when cyclophosphamide, rituximab and lenalidomide (Revlimid) are combined for the treatment of relapsed/refractory of chronic…
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
- Trial name
- NCT01005979
- Testing
- Lenalidomide, Rituximab, and Cyclophosphamide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Emory University
Breast Cancer
De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You
This is a live biobank study for breast cancer (BC) patients where samples will be collected at inflection points in the course of the disease.
- Trial name
- DIGNITY (NCT05134779)
- Testing
- Live Biobank
- Where
- 2 sites in United States
- Volunteers
- 400 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma, Renal Failure
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
The goal of this study is to assess the efficacy of induction treatment with daratumumab-hyaluronidase (dara SC) with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for four cycles in patients with newly diagnosed…
- Trial name
- NCT06142396
- Testing
- Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Augusta University
Type 1 Diabetes
Personalized Comprehensive Diabetes Support for Children With Newly Diagnosed Type 1 Diabetes
The goal of this clinical trial is to learn if access to a diabetes coach improves quality of life (QOL) for families of children with newly diagnosed type 1 diabetes. The main questions it aims to answer are: 1.
- Trial name
- NCT06057662
- Testing
- personalized comprehensive diabetes support
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
GVHD, Chronic
Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)
This is a phase 2, open-label, multicenter trial to evaluate the efficacy and safety of BN101 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least First Line of systemic therapy.
- Trial name
- NCT04930562
- Testing
- BN101
- Where
- 7 sites in China
- Volunteers
- 30 people
- Sponsor
- BioNova Pharmaceuticals (Shanghai) LTD.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.